Frequency of anti-HCV antibodies detection in different histological subtypes in a cohort of 384 B-cell lymphoma patients with HCV serology tested at diagnosis and treated at the Oncology Institute of Southern Switzerland between 2000 and 2013
CI indicates confidence interval.
*One-sided 97.5% CI.
†This estimate of HCV prevalence among B-cell lymphoma may be biased. Indeed, ∼550 additional lymphoma patients seen in the same period were not tested for HCV at diagnosis. Most likely, patients with an expected increased risk for the infection (eg, those from endemic countries, those with a history of blood transfusions or of intravenous use of drugs, and those with elevate transaminases or a history of liver disease) were tested more frequently than the others, leading to a potential overestimation of the HCV prevalence.
